Incyte Announces New Data from Phase 2 Study Evaluating Ruxo

Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa , reinforcing efficacy and safety profile of ruxolitinib cream




Results presented as a late-breaking...

Related Keywords

United States , Ohio , San Diego , California , America , American , Hidradenitis Suppurativa , Incyte Corporation , Exchange Commission , Youtube , Rare Diseases Information Center , National Center , Instagram , Linkedin , Facebook , International Hidradenitis Suppurativa Severity Score System , Us Food Drug Administration , European Academy Of Dermatology , American Academy Of Dermatology , Late Breaking Research , American Academy , Annual Meeting , Skin Pain Numeric Rating Scale , Hidradenitis Suppurativa Clinical Response , Drug Administration , Mississippi River , Full Prescribing Information , Boxed Warning , Medication Guide , North America , Advancing Translational Science Genetic , Rare Diseases Information , Accessed February , Janus Kinase , European Academy , Markets ,